167 related articles for article (PubMed ID: 28465589)
41. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
Gondi CS; Lakka SS; Yanamandra N; Siddique K; Dinh DH; Olivero WC; Gujrati M; Rao JS
Oncogene; 2003 Sep; 22(38):5967-75. PubMed ID: 12955075
[TBL] [Abstract][Full Text] [Related]
42. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
43. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
[TBL] [Abstract][Full Text] [Related]
44. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
46. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Persson M; Juhl K; Rasmussen P; Brandt-Larsen M; Madsen J; Ploug M; Kjaer A
Mol Pharm; 2014 Aug; 11(8):2796-806. PubMed ID: 24955765
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo inhibition of proangiogenic retinal phenotype by an antisense oligonucleotide downregulating uPAR expression.
Lulli M; Cammalleri M; Granucci I; Witort E; Bono S; Di Gesualdo F; Lupia A; Loffredo R; Casini G; Dal Monte M; Capaccioli S
Biochem Biophys Res Commun; 2017 Aug; 490(3):977-983. PubMed ID: 28666875
[TBL] [Abstract][Full Text] [Related]
48. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
49. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Stahl A; Mueller BM
Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
[TBL] [Abstract][Full Text] [Related]
50. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching.
Semina E; Rubina K; Sysoeva V; Rysenkova K; Klimovich P; Plekhanova O; Tkachuk V
Eur J Cell Biol; 2016 Sep; 95(9):295-310. PubMed ID: 27324124
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus.
Boer JC; Domanska UM; Timmer-Bosscha H; Boer IG; de Haas CJ; Joseph JV; Kruyt FA; de Vries EG; den Dunnen WF; van Strijp JA; Walenkamp AM
Br J Cancer; 2013 Feb; 108(3):587-96. PubMed ID: 23322202
[TBL] [Abstract][Full Text] [Related]
52. Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme.
Laurenzana A; Biagioni A; D'Alessio S; Bianchini F; Chillà A; Margheri F; Luciani C; Mazzanti B; Pimpinelli N; Torre E; Danese S; Calorini L; Del Rosso M; Fibbi G
Oncotarget; 2014 Jun; 5(11):3711-27. PubMed ID: 25003596
[TBL] [Abstract][Full Text] [Related]
53. Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.
Bifulco K; Votta G; Ingangi V; Di Carluccio G; Rea D; Losito S; Montuori N; Ragno P; Stoppelli MP; Arra C; Carriero MV
Oncotarget; 2014 Jun; 5(12):4154-69. PubMed ID: 24980826
[TBL] [Abstract][Full Text] [Related]
54. Zebrafish-Based Screening Models for the Identification of Anti-Metastatic Drugs.
Nakayama J; Makinoshima H
Molecules; 2020 May; 25(10):. PubMed ID: 32455810
[TBL] [Abstract][Full Text] [Related]
55. Application of small molecule FPR1 antagonists in the treatment of cancers.
Ahmet DS; Basheer HA; Salem A; Lu D; Aghamohammadi A; Weyerhäuser P; Bordiga A; Almeniawi J; Rashid S; Cooper PA; Shnyder SD; Vinader V; Afarinkia K
Sci Rep; 2020 Oct; 10(1):17249. PubMed ID: 33057069
[TBL] [Abstract][Full Text] [Related]
56. D2A-Ala peptide derived from the urokinase receptor exerts anti-tumoural effects in vitro and in vivo.
Furlan F; Eden G; Archinti M; Arnaudova R; Andreotti G; Citro V; Cubellis MV; Motta A; Degryse B
Peptides; 2018 Mar; 101():17-24. PubMed ID: 29273518
[TBL] [Abstract][Full Text] [Related]
57. Development of potent isoflavone-based formyl peptide receptor 1 (FPR1) antagonists and their effects in gastric cancer cell models.
Francavilla F; Sarcina F; Schepetkin IA; Kirpotina LN; Contino M; Schirizzi A; De Leonardis G; Khlebnikov AI; D'Alessandro R; Quinn MT; Lacivita E; Leopoldo M
Eur J Med Chem; 2023 Dec; 261():115854. PubMed ID: 37839346
[TBL] [Abstract][Full Text] [Related]
58. Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin.
Castaldo V; Minopoli M; Di Modugno F; Sacconi A; Liguoro D; Frigerio R; Ortolano A; Di Martile M; Gesualdi L; Madonna G; Capone M; Cirombella R; Catizone A; Del Bufalo D; Vecchione A; Carriero MV; Ascierto PA; Mancini R; Fattore L; Ciliberto G
J Exp Clin Cancer Res; 2023 Nov; 42(1):317. PubMed ID: 38008717
[TBL] [Abstract][Full Text] [Related]
59. Topoisomeric Membrane-Active Peptides: A Review of the Last Two Decades.
Carrera-Aubesart A; Gallo M; Defaus S; Todorovski T; Andreu D
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896211
[TBL] [Abstract][Full Text] [Related]
60. Peptide modulators of cell migration: Overview, applications and future development.
Gattringer J; Gruber CW; Hellinger R
Drug Discov Today; 2023 May; 28(5):103554. PubMed ID: 36921670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
